It is our goal to improve and help change the way care is delivered for people with hemophilia in the developing world. To help achieve this, Biogen and Swedish Orphan Biovitrum (Sobi) are working with the World Federation of Hemophilia (WFH) to help transform the humanitarian aid model for people with hemophilia in the developing world. In 2014, Biogen and Sobi announced their intent to produce and donate one billion international units (IUs) of clotting factor therapy for humanitarian use, of which up to 500 million IUs will be donated to the WFH over the next five years. This donation is the largest of its kind to help people with hemophilia in developing countries and will substantially increase the amount of hemophilia therapy available in the developing world. It is designed to help enable a predictable, sustained humanitarian supply of factor therapy with a goal of improving the way care is delivered for people with hemophilia living in places where treatment is scarce and access is limited.
This is a first step to what we hope will be a collective effort across the global hemophilia community to make similar donations in order to create a sustainable model for humanitarian support. Our vision is that one day, in every part of the world, all people with hemophilia can receive the care they need regardless of where they live.
Closing the Treatment Gap in the Developing World
By John Cox, Executive Vice President, Pharmaceutical Operations & Technology